PDCD1 and hepatocellular carcinoma: Similarly, MCT4 inhibition improves programmed cell death protein 1 (PD‒1) blockade efficacy in hepatocellular carcinoma (HCC) models, suggesting a potential therapeutic strategy for ICI‒resistant HCC patients (Chen et al., 2022).